



## Vaccinia Virus Vectors and Methods to Prevent the Pathology Caused by Infectious Agents

AzTE Cases M01-021 & M01-044

### Inventors

#### Bertram Jacobs

Professor  
The Biodesign Institute  
Arizona State University

#### Jeffrey Langland

Associate Research Professor  
The Biodesign Institute  
Arizona State University

#### Sangeetha Vijaysri

Graduate Research Associate  
The Biodesign Institute  
Arizona State University

#### Teresa Brandt

Graduate Research Assistant  
The Biodesign Institute  
Arizona State University

#### Alexander Rich

Professor  
Massachusetts Institute of  
Technology

### Intellectual Property

#### Status:

US 6,750,043 B2

US 6,942,855 B2

US 7,001,718 B2

### Contact

*Yash Vaishnav, PhD, MBA*

Vice President

Business Development, Life  
Sciences

Arizona Technology  
Enterprises, LLC (AzTE)

P: 480.884.1648

F: 847.971.2871

[YASH@AZTE.COM](mailto:YASH@AZTE.COM)

[HEALTHSCIENCES@AZTE.COM](mailto:HEALTHSCIENCES@AZTE.COM)

### Invention Description

The vaccinia virus, when used for various clinical applications, is quite versatile and potentially very beneficial to human health. In addition to its utilization as a smallpox vaccine, the vaccinia virus is extensively used as an effective expression vector since it is easy to isolate, can accommodate vast amounts of exogenous DNA and has a wide host range. Foreign genetic material, which is incorporated into the vaccinia genome, may encode for antigens and other useful molecules, including anticancer agents. Unfortunately, while the vaccinia virus has many potentially valuable applications, the form of the vaccinia virus currently in use poses certain dangers to human health including the risk of a life-threatening vaccinia infection.

Researchers at the Biodesign Institute of Arizona State University and their collaborators at the Massachusetts Institute of Technology have developed a form of vaccinia virus with genetic modifications that decrease the risk of recipient viral infection. These genetic modifications allow for the virus to be recombined with and used to deliver foreign genetic material for the purposes of immunization or other useful molecule delivery or it can be used in its given form to elicit an immune response in mammals that will protect against the smallpox disease.

The modified vaccinia virus, with its low virulence but increased efficacy, has numerous applications especially owing to the wide variety of foreign DNA that can be recombined with the virus.

### Potential Applications

- Gene therapy vector
- Delivery of anticancer agents and other medically useful molecules
- Immunization against various diseases in mammals
- Smallpox vaccine

### Benefits and Advantages

- Reduced Pathogenicity – reduced pathogenicity decreases the chance of side effects such as host infection and excessive host immune response
- Increased Effectiveness – the reduced pathogenicity of the modified virus has the potential to allow the virus to live longer in the infected host and thus produce a more robust immune response or, in the case of a gene therapy vector, allow for the production of higher levels of the protein encoded for delivery